Literature DB >> 34592239

Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.

Michael Torbenson1, Chantal E McCabe2, Daniel R O'Brien2, Jun Yin3, Tiffany Bainter3, Nguyen H Tran4, Saba Yasir5, Zongming Eric Chen5, Renu Dhanasekaran6, Keun Soo Ahn7, Lewis R Roberts8, Chen Wang2.   

Abstract

Beta-catenin (CTNNB1) is commonly mutated in hepatocellular carcinoma (HCC). CTNNB1-mutated HCC has important clinical correlates, such as being immune cold and less likely to respond to immune checkpoint inhibitor therapies. It remains unclear, however, if they are a morphologically homogenous group of tumors. To better understand the association between the morphology, CTNNB1 mutations, and other molecular features, a detailed study of 338 The Cancer Genome Atlas cases was performed. A characteristic histological morphology was strongly associated with CTNNB1 mutations but was present in only 58% of CTNNB1-mutated HCCs. Tumors with APC mutations tended to have the classic morphology; those with AXIN mutations did not. Pseudoglands are a key feature of the classic morphology, and they were associated with CTNNB1 mutations, male gender, specific CTNNB1 mutation site, and lack of TP53 mutations. Differential gene expression analysis stratified by the presence/absence of pseudoglands identified 60 differentially expressed genes (FDR <5%); clustering according to these differentially expressed genes revealed three groups of tumors, one with pseudoglands and a strong association with genes regulated by Wnt signaling; within this group, TP53 mutations were associated with a loss of the typical morphology of CTNNB1-mutated HCCs. When stratified by gender, further differential gene expression showed Wnt-regulated genes were associated with pseudoglands in men but not women. These findings indicate HCC with CTNNB1 mutations are morphologically heterogeneous, with gene penetrance for morphology dependent in part on gender, specific CTNNB1 mutations, and co-occurring TP53 mutations. This heterogeneity has important implications for the classification of HCC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APC; AXIN; CTNNB1; Differential gene expression; Survival

Mesh:

Substances:

Year:  2021        PMID: 34592239      PMCID: PMC9258524          DOI: 10.1016/j.humpath.2021.09.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.526


  17 in total

1.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis.

Authors:  P Laurent-Puig; P Legoix; O Bluteau; J Belghiti; D Franco; F Binot; G Monges; G Thomas; P Bioulac-Sage; J Zucman-Rossi
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.

Authors:  J Zucman-Rossi; S Benhamouche; C Godard; S Boyault; G Grimber; C Balabaud; A S Cunha; P Bioulac-Sage; C Perret
Journal:  Oncogene       Date:  2006-09-11       Impact factor: 9.867

3.  Glutamine synthetase immunostaining correlates with pathologic features of hepatocellular carcinoma and better survival after radiofrequency thermal ablation.

Authors:  Barbara Dal Bello; Laura Rosa; Nicoletta Campanini; Carmine Tinelli; Francesca Torello Viera; Gioacchino D'Ambrosio; Sandro Rossi; Enrico M Silini
Journal:  Clin Cancer Res       Date:  2010-03-16       Impact factor: 12.531

4.  Hepatocellular Neoplasms Arising in Association With Androgen Use.

Authors:  Sounak Gupta; Bita V Naini; Richard Munoz; Rondell P Graham; Benjamin R Kipp; Michael S Torbenson; Taofic Mounajjed
Journal:  Am J Surg Pathol       Date:  2016-04       Impact factor: 6.394

5.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.

Authors:  J T Nhieu; C A Renard; Y Wei; D Cherqui; E S Zafrani; M A Buendia
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

6.  Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.

Authors:  V Audard; G Grimber; C Elie; B Radenen; A Audebourg; F Letourneur; O Soubrane; M-C Vacher-Lavenu; C Perret; C Cavard; B Terris
Journal:  J Pathol       Date:  2007-07       Impact factor: 7.996

7.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

8.  Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.

Authors:  Haibin Song; Zhuo Yu; Xuehua Sun; Jun Feng; Qi Yu; Hanif Khan; Xiaojun Zhu; Lingying Huang; Man Li; Myth T S Mok; Alfred S L Cheng; Yueqiu Gao; Hai Feng
Journal:  EBioMedicine       Date:  2018-08-24       Impact factor: 8.143

9.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Authors:  Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; Subhiksha Nandakumar; Joshua Armenia; Danny N Khalil; Melanie Albano; Michele Ly; Jinru Shia; Jaclyn F Hechtman; Ritika Kundra; Imane El Dika; Richard K Do; Yichao Sun; T Peter Kingham; Michael I D'Angelica; Michael F Berger; David M Hyman; William Jarnagin; David S Klimstra; Yelena Y Janjigian; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-29       Impact factor: 12.531

10.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.

Authors: 
Journal:  Cell       Date:  2017-06-15       Impact factor: 66.850

View more
  2 in total

1.  Multi-omics subtyping of hepatocellular carcinoma patients using a Bayesian network mixture model.

Authors:  Polina Suter; Eva Dazert; Jack Kuipers; Charlotte K Y Ng; Tuyana Boldanova; Michael N Hall; Markus H Heim; Niko Beerenwinkel
Journal:  PLoS Comput Biol       Date:  2022-09-06       Impact factor: 4.779

Review 2.  Targeting Wnt/β-Catenin Pathways in Primary Liver Tumours: From Microenvironment Signaling to Therapeutic Agents.

Authors:  Federico Selvaggi; Teresa Catalano; Roberto Cotellese; Gitana Maria Aceto
Journal:  Cancers (Basel)       Date:  2022-04-10       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.